Omega Therapeutics Could Offer 'Intriguing' Liver Cancer Drug, Analyst Says

  • HC Wainwright has initiated coverage on Omega Therapeutics Inc OMGA with a Buy rating and a price target of $11.
  • The analyst writes that the company's platform appears applicable to a wide array of therapeutic indications ranging from oncology to multigenic diseases, including immunology and regenerative medicine.
  • The company's lead program, OTX-2002, is in a Phase 1/2 trial for relapsed or refractory hepatocellular carcinoma.
  • HC Wainwright says that OTX-2002 could prove an intriguing new HCC drug, possibly in combination with either sunitinib or another approved agent, lenvatinib.
  • Related: Omega Therapeutics Touts Encouraging Preclinical Data In Liver Cancer Animal Models.
  • The Phase 1/2 trial utilizes a two-part design, with Part 1 involving dose escalation to determine the safety profile, followed by a monotherapy expansion cohort to conduct a preliminary assessment of efficacy using objective response rate (ORR) and duration of response (DOR) parameters.
  • Part 2 shall assess the combination of OTX-2002 and standard-of-care (SOC) treatment with kinase inhibitors in HCC patients. 
  • Data from Part 1 will be released in 1H23, followed by Part 2 data in late 2023.
  • The analyst notes that from a vantage point, the HCC and NSCLC indications are lucrative arenas with peak sales potential of $750 million and $6.7 billion by 2035, respectively.
  • Price Action: OMGA shares are up 10.8% at $6.98 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: BiotechNewsHealth CareInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!